Latest Articles
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - Targeted Oncology
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer Targeted Oncology
Published: Jan. 22, 2026, 4:02 p.m.
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer - targetedonc.com
Fruquintinib/Sintilimab Yields Efficacy, Safety in Advanced pMMR Endometrial Cancer targetedonc.com
Published: Jan. 22, 2026, 4:02 p.m.
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations - OncLive
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations OncLive
Published: Dec. 26, 2025, 1:19 p.m.
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial - geneonline.com
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com
Published: Dec. 21, 2025, 12:34 p.m.
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive
Published: Nov. 26, 2025, 7:03 p.m.
DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management - OncLive
DUO-E Post Hoc Analysis Suggests Potential for Biomarker-Optimized pMMR Endometrial Cancer Management OncLive
Published: May 6, 2025, 2:01 p.m.
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups - OncLive
Dr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups OncLive
Published: March 17, 2025, 5:39 p.m.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer - OncLive
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer OncLive
Published: March 15, 2025, 4:52 p.m.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer - OncLive
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Published: Dec. 3, 2024, 5:11 p.m.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer - OncLive
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer OncLive
Published: July 1, 2024, 7 a.m.
Link copied to clipboard!